1) Pegstim is indicated for: a) Reduction in the duration of neutropenia in patients treated with cytotoxic chemotherapy for malignancy b) Reduction in the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy c) Decrease the risk of febrile neutropenia in patients with non-myeloid malignancies d) All of the above 2) What is the dosing of Pegstim? a) 6 mg, 24 hour after the chemotherapy b) 6 mg, 24 hour before the chemotherapy c) 6 mg, 14 days before administration cytotoxic chemotherapy d) 6 mg, 14 weeks before administration cytotoxic chemotherapy

Tauler de classificació

Estil visual

Opcions

Canvia de fonament

Restaurar desada automàtica: ?